THE PROCTER & GAMBLE COMPANY

Shareholders of The Procter & Gamble Company

The Procter & Gamble Company is a widely held New York Stock Exchange issuer with no controlling shareholder and no dual-class share structure. Its 2026 proxy statement records that each share of Company stock — common stock and both series of ESOP Convertible Class A Preferred Stock alike — carries one vote. At the record date of 14 August 2026 there were 2,322,672,312 common shares, 18,253,277 Series A ESOP Convertible Class A Preferred shares and 48,641,998 Series B ESOP Convertible Class A Preferred shares issued and outstanding; the preferred series are employee-plan stock held through the Company’s Profit Sharing Trust and Employee Stock Ownership Plan. Only two holders of more than 5% of any class are disclosed in the proxy statement filed on 28 August 2026, both of them index-fund managers holding in the ordinary course of business. This is a disclosure of reportable holders only, not a list of P&G shareholders: holders below the 5% Schedule 13G threshold are not published, and the disclosed positions together account for about 14% of the common stock.

Percentages are as calculated in the proxy statement against 2,323,858,841 common shares outstanding at 30 June 2026. The BlackRock figure rests on a filing that is more than two and a half years old and has not been amended; no Schedule 13G or 13D from any other holder has been filed against the P&G CUSIP (742718109) since January 2024.

A change of reporting entity affects the Vanguard position and is easy to miss. Following an internal realignment on 12 January 2026, The Vanguard Group, Inc. filed Amendment No. 12 to its Schedule 13G on 27 March 2026 reporting nil P&G shares — zero sole and shared voting power, zero dispositive power, 0% of class — and stating that subsidiaries and business divisions that formerly reported with it would report separately. The position is now reported by Vanguard Capital Management, which filed a new Schedule 13G on 30 April 2026. Any dataset still naming “Vanguard Group Inc” as a current P&G holder is stale as to the entity, not only as to the number.

Ultimate beneficial ownership

No ultimate beneficial owner is identified, and none can be. The Procter & Gamble Company has no parent and no controlling shareholder; the largest disclosed position is 7.52%, far below any beneficial-ownership control threshold, and it is held by an investment adviser on behalf of registered investment companies and managed accounts rather than for its own account. The two disclosed holders certified in their Schedules 13G that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The United States does not operate a public beneficial-ownership register for listed corporations, so no register entry exists to consult.

Data availability

Major shareholders only. For a US listed company the published record consists of Schedule 13D/13G filings by holders crossing 5% and the annual proxy statement’s beneficial-ownership table; there is no public share register, no complete shareholder list and no public UBO register. Absence of further names is a consequence of the disclosure regime, not evidence that no other significant holders exist.

Defects found in the baseline data on this record. The stored gd_shareholders field holds four institutional fund rows, verified 4 September 2026, whose percentages do not reconcile with the shares in issue and must not be relied on. Against the 2,324,433,060 common shares outstanding at 31 July 2026 stated on the Form 10-K cover, the stored figures are overstated by roughly 2.2 times in every row: “Vanguard Group Inc” 237,459,756 shares is stored at 21.96% when that quantity is 10.2% of the shares in issue; SPDR S&P 500 ETF Trust 28,461,787 shares is stored at 2.64% against an actual 1.22%; iShares Core S&P 500 ETF 30,381,056 shares at 2.81% against 1.31%; and Fidelity 500 Index Fund 29,551,226 shares at 2.73% against 1.27%. Separately, the four rows are reportable or estimated fund positions, not the shareholder base, and the row naming “Vanguard Group Inc” names an entity that has reported nil since 27 March 2026.

Sources

• US Securities and Exchange Commission — The Procter & Gamble Company, Definitive Proxy Statement (DEF 14A), filed 28 August 2026, beneficial ownership and voting sections. https://www.sec.gov/Archives/edgar/data/80424/000119312526372211/pg-20260826.htm Retrieved 25 September 2026.
• US Securities and Exchange Commission — Schedule 13G, Vanguard Capital Management on The Procter & Gamble Company, filed 30 April 2026 (event date 31 March 2026). https://www.sec.gov/Archives/edgar/data/80424/000210011926000950/primary_doc.xml Retrieved 25 September 2026.
• US Securities and Exchange Commission — Schedule 13G/A Amendment No. 12, The Vanguard Group on The Procter & Gamble Company, filed 27 March 2026, reporting nil holdings. https://www.sec.gov/Archives/edgar/data/80424/000010290926002031/primary_doc.xml Retrieved 25 September 2026.
• US Securities and Exchange Commission — Schedule 13G/A, BlackRock, Inc. on The Procter & Gamble Company, filed 29 January 2024 (data as of 31 December 2023). https://www.sec.gov/Archives/edgar/data/80424/000108636424005082/us7427181091_012924.txt Retrieved 25 September 2026.
• US Securities and Exchange Commission — The Procter & Gamble Company, Annual Report on Form 10-K for the fiscal year ended 30 June 2026, filed 4 August 2026, cover page share count. https://www.sec.gov/Archives/edgar/data/80424/000008042426000103/pg-20260630.htm Retrieved 25 September 2026.

Directors and officers of The Procter & Gamble Company

The Procter & Gamble Company has a single-tier board. Thirteen directors were serving at the date of the proxy statement filed on 28 August 2026, of whom twelve stand for election at the annual meeting on 13 October 2026; Debra L. Lee is retiring from the Board and is not standing for re-election. Eleven of the twelve nominees are identified by the Company as independent, the exception being Shailesh G. Jejurikar, who is Chairman of the Board, President and Chief Executive Officer. Joseph Jimenez has served as independent Lead Director since 2021. Separately, the Form 10-K filed on 4 August 2026 names eleven executive officers as at that date. Board turnover has been high: Terry J. Lundgren and Patricia A. Woertz retired from the Board effective 14 October 2025 and Jon R. Moeller left it on 31 July 2026, and the Company states that eight of its twelve nominees have a tenure of less than five years. Nationality is not disclosed for any director or officer, because United States securities filings do not record it.

Board of directors at 28 August 2026

Executive officers as at 4 August 2026

Recent officer changes

• Chief executive succession. As announced on 28 July 2025 and effective 1 January 2026, Shailesh G. Jejurikar became President and Chief Executive Officer and Jon R. Moeller became Executive Chairman. On 28 July 2026 the Board appointed Mr Jejurikar Chairman of the Board, effective 1 August 2026, recombining the Chairman and Chief Executive roles. Source: Form 8-K filed 29 July 2026; 2026 proxy statement.
• Departure of the Executive Chairman. Jon R. Moeller retired as Executive Chairman and as a member of the Board effective 31 July 2026 and retired from the Company on 14 August 2026. Source: Form 8-K filed 29 July 2026; 2026 proxy statement.
• Three segment chief executives replaced. Jennifer L. Davis stepped down as Chief Executive Officer – Health Care on 1 April 2026 and retired on 30 June 2026; Ma. Fatima D. Francisco stepped down as Chief Executive Officer – Baby, Feminine and Family Care on 1 June 2026 and retires on 4 September 2026; Gary A. Coombe stepped down as Chief Executive Officer – Grooming on 1 July 2026 and retires on 30 September 2026. Source: 2026 proxy statement.

Data availability

Current only, from company filings. Ohio does not publish a directors’ or officers’ register for corporations, so the authoritative sources here are the Company’s own Form 10-K Part I list of executive officers, its proxy statement and its Forms 8-K. Appointment dates are published as years rather than exact dates for board service and for the year in which an executive was first elected an officer; exact effective dates are available only for the changes announced on Form 8-K. Nationality is not disclosed and is not a field in any of these filings; countries of residence and correspondence addresses are not published either. Neither the Ohio Secretary of State business search (businesssearch.ohiosos.gov) nor ohiosos.gov could be reached from either of the two hosts used for this research on 25 September 2026 — both returned an official “Website Maintenance” page — so the state register’s own record of this entity could not be inspected.

Defects found in the baseline data on this record. The stored gd_officers field holds 125 rows and should not be read as a current officer list. Every row is flagged ACTIVE and not one carries an appointment or resignation date, so no row can be dated or retired. The set mixes current executive officers with people who no longer hold the recorded position — it lists Jennifer L. Davis as Chief Executive Officer of Health Care, Ma. Fatima D. Francisco as chief executive of Baby and Feminine Care and Gary A. Coombe as Chief Executive Officer – Grooming, all three of whom stepped down during 2026, and Jon R. Moeller as “President, Ceo & Chairman Of The Board”, a role he left on 31 July 2026. None of the twelve directors standing at the 2026 annual meeting other than Mr Jejurikar appears anywhere in the 125 rows, so the file contains no independent director at all. It also duplicates individuals under variant spellings (“Jon R. Moeller”, “JON MOELLER”, “JOHN MOELLER”; “ERIC ROSENFELD” and “ERIK ROSENFELD”; “PHILIP LONG” and “LONG PHILIP”), assigns the same person several conflicting titles, and includes rows whose job title is “Processor”, “Member” or “Manager” — not officer roles of the registrant. The names and titles below the executive-officer level appear to be drawn from subsidiary and benefit-plan records rather than from the registrant’s own filings.

Sources

• US Securities and Exchange Commission — The Procter & Gamble Company, Annual Report on Form 10-K for the fiscal year ended 30 June 2026, filed 4 August 2026, “Information about our Executive Officers”. https://www.sec.gov/Archives/edgar/data/80424/000008042426000103/pg-20260630.htm Retrieved 25 September 2026.
• US Securities and Exchange Commission — The Procter & Gamble Company, Definitive Proxy Statement (DEF 14A) for the annual meeting of 13 October 2026, filed 28 August 2026, director nominee biographies, committee membership and leadership changes. https://www.sec.gov/Archives/edgar/data/80424/000119312526372211/pg-20260826.htm Retrieved 25 September 2026.
• US Securities and Exchange Commission — The Procter & Gamble Company, Current Report on Form 8-K, Item 5.02, filed 29 July 2026. https://www.sec.gov/Archives/edgar/data/80424/000008042426000094/pg-20260729.htm Retrieved 25 September 2026.

Group structure of The Procter & Gamble Company

The Procter & Gamble Company is the ultimate parent of the P&G group. It has no parent entity: it is a listed Ohio corporation with no controlling holder, and none of its securities filings records an immediate or ultimate parent. Exhibit 21 to the Form 10-K for the fiscal year ended 30 June 2026 lists 239 subsidiaries, organised in 79 jurisdictions — 52 of them under the law of nine US states and territories (Delaware 23, Ohio 19, plus California, Florida, Massachusetts, Minnesota, New Jersey, Puerto Rico and Vermont) and 187 under the law of 70 other countries, the largest groupings being China 16, the United Kingdom 15, Germany 10, Switzerland 8, and the Netherlands, India and France 6 each. The exhibit is dated as of 30 June 2026 and states that it omits entities with de minimis activity that would not together constitute a significant subsidiary, so it is a near-complete rather than an exhaustive list. Two group companies are themselves stock-exchange listed, both in India, and their regulatory shareholding disclosures give exact percentages that the US filings do not.

Verified corporate relationships

Recent structural changes

• Glad joint venture ended, January 2026. The Glad joint venture agreement between the Company and The Clorox Company expired in January 2026. Under its terms Clorox purchased the Company’s minority interest in the venture at fair market value for USD 476 million, and the Company accounted for the transaction as a dissolution of the joint venture business, recording an after-tax gain of USD 261 million. Source: Form 10-K for the year ended 30 June 2026.
• Limited market portfolio restructuring completed, quarter ended 30 September 2024. The Company completed the restructuring of operations in certain Enterprise Markets with the substantial liquidation of its operations in Argentina, recording incremental restructuring charges of USD 801 million after tax in that quarter and USD 1.2 billion after tax across the programme. Source: Form 10-K for the year ended 30 June 2026.
• Thorne acquisition agreed but not completed, 4 August 2026. The Company entered into an agreement to acquire Thorne, a premium wellness and supplement brand, for USD 3.8 billion, and expects the transaction to close in the second quarter of fiscal 2027 subject to regulatory approval and customary closing conditions. It is a pending acquisition and Thorne is not part of the group at the date of this profile. Source: Form 10-K for the year ended 30 June 2026, Note 15 Subsequent Event.

Data availability

Subsidiaries only, and without percentages. Exhibit 21 names the subsidiaries and their jurisdiction of organisation but gives no registration numbers, no ownership percentages and no intermediate holding chain, and it omits de minimis entities by design. The United States has no register of corporate groups, so ownership percentages inside the group are available only where a local register or a listed subsidiary’s own regulatory disclosure supplies them — in this profile, the Indian shareholding patterns filed under SEBI Regulation 31 and the UK persons-with-significant-control register. The UK PSC entry records a control band, not an exact percentage. The Ohio Secretary of State business search could not be reached on 25 September 2026 and returned an official “Website Maintenance” page, so nothing was verified against the state register.

Notes on the baseline data on this record. The stored gd_groups tree is correctly rooted on The Procter & Gamble Company and holds 259 nodes, but carries no relationship type, no ownership percentage and no date on any node, so it records adjacency only and cannot support a statement about control. Its identifiers are of mixed type — VAT numbers, tax codes, state file numbers and unlabelled provider identifiers — and several are not registration numbers at all. A number of its nodes appear in neither Exhibit 21 nor the Indian promoter-group lists, among them “Procter Outdoor Inc” (Florida P01000059831), “District Pet Imaging, LLC”, “Beverly Giorgio Hills Inc” and “PGT Healthcare LLP”; because Exhibit 21 omits de minimis entities, that absence is not by itself proof of error, but those entries are unverified and none of them is relied on above. One node is spelled “PROCTOR & GAMBLE”. Conversely the tree omits group companies that appear in the Indian promoter-group disclosures, including the Fater joint-venture companies, so it is neither complete nor fully verified in either direction.

Sources

• US Securities and Exchange Commission — The Procter & Gamble Company, Exhibit 21 (Subsidiaries of the Registrant) to the Annual Report on Form 10-K for the fiscal year ended 30 June 2026, filed 4 August 2026. https://www.sec.gov/Archives/edgar/data/80424/000008042426000103/fy252610-kexhibit21.htm Retrieved 25 September 2026.
• US Securities and Exchange Commission — The Procter & Gamble Company, Annual Report on Form 10-K for the fiscal year ended 30 June 2026, filed 4 August 2026 (Recent Developments; Note 15). https://www.sec.gov/Archives/edgar/data/80424/000008042426000103/pg-20260630.htm Retrieved 25 September 2026.
• Procter & Gamble Hygiene and Health Care Limited — Shareholding Pattern under SEBI (LODR) Regulation 31 for the quarter ended 30 June 2026, published on the company’s investor page. https://assets.ctfassets.net/oe48y40ukei6/6Y63mq90qqR1GwEtqmKPA/600bb19742cb70b99f01ee26871e3429/Shareholding_Pattern_for_the_quarter_ended_June_30__2026.pdf Retrieved 25 September 2026.
• Gillette India Limited — Shareholding Pattern under SEBI (LODR) Regulation 31 for the quarter ended 31 March 2026, published on the company’s investor page. https://assets.ctfassets.net/oe48y40ukei6/7vLDLjeUTwbFSP5bxgJgWN/fd269ef78af93bcb9a972254d35b0cea/Shareholding_Pattern_for_the_quarter_ended_March_31_2026.pdf Retrieved 25 September 2026.
• Companies House (United Kingdom) — PROCTER & GAMBLE LIMITED, company 00083758, persons with significant control; entry for The Procter & Gamble Company notified 11 March 2021. https://find-and-update.company-information.service.gov.uk/company/00083758/persons-with-significant-control Retrieved 25 September 2026.